3Wadleigh M, Tef{eri A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria[J], lnt J Hematol, 2010, 91(2) 174-179. 被引量：1
4Ch[o6 J, VaI6rie U, Jean-Pierre LC, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J]. Nature, 2005, 434(7037): 1144- 1148. 被引量：1
5Antonioli E, Guglielmelli P, Poll G, et al. Influence of JAK2 V617F allele burden on phenotypc in essential thrombocythemia [J]. Haematologica, 2008, 93(l):41-48. 被引量：1
6Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2V617F mutation status: a prospective study [J]. Lancet, 2005,366(9501) .- 1945-1953. 被引量：1
7Vassiliou GS, Campbell PJ, Li J, et al. An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X- inactivation [J]. Haematologica, 2006, 91(8) :1100-1104. 被引量：1
8Barbui, Tiziano. How to manage thrombosis in myeloproliferative neoplasms[J]. Curr Opin Oncol, 2011, 23 (6) : 654-658. 被引量：1
9Parikh S, Shah R, Kapoor P. Portal vein thrombosis[J]. Am J Med, 2010,123(2): 111-119. 被引量：1
10Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis[J]. N EnglJ Med, 2001, 345(23) : 1683-1688. 被引量：1
